Keywords
Candida albicans
carriers
in vitro sensitivity
Fluconazole
Voriconazole
How to Cite
Plaudit
Abstract
Objective: The aim of this study was to determine the percentage of Candida spp carriers working in critical areas of hospitals in Metropolitan Lima. Methodology: Descriptive and cross-sectional study at the Faculty of Medical Technology, Universidad Nacional Federico Villarreal, Lima, Peru, the sample was 75 staff members working in critical areas of a hospital in Metropolitan Lima, in April and May 2024, samples of hands and oral cavity of 75 staff members were collected and cultured on plates with Sabouraud agar (AGS) and Mycosel and identified by conventional methods. Results: Yeast isolates were tested for growth capacity at 42°C, resistance to cycloheximide, germ tube production, phospholipases and proteinases, and in vitro sensitivity to fluconazole and voriconazole was determined by Kirby Bauer disk diffusion method, according to CLSI. Identification of Candida spp. yeasts. Conclusions: 50.6% of the participants were positive for the isolation of Candida spp. the most frequently isolated species was Candida parapsilosis in hands, followed by C. albicans in oral cavity, these findings motivate to improve preventive measures in patient care, to intensify hand hygiene regulations and to encourage, in other hospital centers, the execution of these investigations, in order to reduce hospital outbreaks of horizontal transmission.
References
Asogan M, Kim HY, Kidd S, Alastruey-Izquierdo A, Govender NP, Dao A, Shin JH, Heim J, Ford NP, Gigante V, Sati H, Morrissey CO, Alffenaar JW, Beardsley J. Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list. Med Mycol. 2024 Jun 27; 62(6):myad131. Doi: 10.1093/mmy/myad131. PMID: 38935912; PMCID: PMC11210616.
Branco, J., Miranda, I. M., & Rodrigues, A. G. (2023). Virulencia de Candida parapsilosis y mecanismos de Resistencia a los antifúngicos: Una revisión exhaustiva de los determinantes clave. Journal of Fungi, 9(1), 80. https://doi.org/10.3390/jof9010080
Brilhante RSN, Sales JA, da Silva MLQ, de Oliveira JS, Pereira LA, Pereira-Neto WA, Cordeiro RA, Sidrim JJC, Castelo-Branco DSCM, Rocha MFG. Antifungal susceptibility and virulence of Candida parapsilosis species complex: an overview of their pathogenic potential. J Med Microbiol. 2018 Jul; 67(7):903-914. Doi: 10.1099/jmm.0.000756. Epub 2018 May 30. PMID: 29846153.
Barchiesi F, Orsetti E, Osimani P, Catassi C, Santelli F et al. Factors related to outcome of bloodstream infections due to Candida parapsilosis complex. BMC Infect Dis 2016; 16:387–394 [View Article][PubMed] [Google Scholar]
Bustamante B, Martins MA, Bonfietti LX, Szeszs MW, Jacobs J, Garcia C, Melhem MSC. Species distribution and antifungal susceptibility profile of Candida isolates from bloodstream infections in Lima, Peru. J Med Microbiol. 2014. Jun. 63(Pt 6):855-860. Doi: 10.1099/jmm.0.071167-0. Epub 2014 Mar 25. PMID: 24667770.
Carrillo-Dover, Pedro, Álvarez-Vega, Carolina, Salas-Campos, Ingrid, & Mora-Brenes, Nury. (2009). Aislamiento de Candida spp. y otras levaduras en el personal que labora en áreas críticas del Hospital San Juan de Dios. Acta Médica Costarricense, 51(3), 165-171.
Cetinkaya O, Ozyurt OK, Kuskucu MA, Ozhak B, Ongut G, Yazisiz H, Ogunc D. Candidemia Cases Caused by Candida parapsilosis Complex Species: Epidemiology and Antifungal Susceptibility of Strains. Clin Lab. 2023 Dec 1; 69(12). Doi: 10.7754/Clin.Lab.2023.230349. PMID: 38084692.
CLSI Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard, CLSI Document M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008 [Google Scholar]
CLSI Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Fourth Informational Supplement, CLSI Document M27-S4. Wayne, PA: Clinical and Laboratory Standards Institute; 2012 [Google Scholar]
Franconi I, Rizzato C, Poma N, Tavanti A, Lupetti A. Candida parapsilosis sensu stricto Antifungal Resistance Mechanisms and Associated Epidemiology. Journal of Fungi. 2023. 9(8):798. https://doi.org/10.3390/jof9080798.
Govrins M, Lass-Flörl C. Candida parapsilosis complex in the clinical setting. Nat Rev Microbiol. 2024. Jan. 22 (1):46-59. Doi: 10.1038/s41579-023-00961-8. Epub 2023 Sep 6. PMID: 37674021.
Lazo, Víctor, Hernández, Gina, & Méndez, Rafael. (2018). Candidiasis sistémica en pacientes críticos, factores predictores de riesgo. Horizonte Médico (Lima), 18(1), 75-85. https://dx.doi.org/10.24265/horizmed.2018.v18n1.11
Parambath S, Dao A, Kim HY, Zawahir S, Izquierdo AA, Tacconelli E, Govender N, Oladele R, Colombo A, Sorrell T, Ramon-Pardo P, Fusire T, Gigante V, Sati H, Morrissey CO, Alffenaar JW, Beardsley J. Candida albicans-A systematic review to inform the World Health Organization Fungal Priority Pathogens List. Med Mycol. 2024 Jun 27; 62(6):myae045. Doi: 10.1093/mmy/myae045. Erratum in: Med Mycol. 2024 Aug 2; 62(8):myae074. Doi: 10.1093/mmy/myae074. PMID: 38935906; PMCID: PMC11210619.
Rodriguez L, Bustamante B, Huaroto L, Agurto C, Illescas R, Ramirez R, et al. A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes. PLoS One. 2017;12 (4): e0175172. Doi: 10.1371/journal.pone.0175172.
Treviño-Rangel, José Gerardo González-González, Elvira Garza-González, Gloria M. González Candida parapsilosis, una amenaza desafiante (Clin Microbiol Rev 2008), pp. 606-625. https://www.elsevier.es/en-revista-medicina-universitaria-304-articulo-candida-parapsilosis-una-amenaza-desafiante-X1665579612676659
Saúl García, Yotsabeth y Hernández Valles, Rosaura. (2014). Aislamiento de Candida SPP. en ambiente y personal que labora en una unidad de cuidados intensivos. Revista de la Sociedad Venezolana de Microbiología, 34(1), 27-32. Recuperado en 01 de febrero de 2024, de http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S1315-25562014000100007&lng=es&tlng=es.
Samantaray S, Singh R. Evaluation of MALDI-TOF MS for Identification of Species in the Candida parapsilosis Complex from Candidiasis Cases. J Appl Lab Med. 2022 Jun 30; 7(4):889-900. Doi: 10.1093/jalm/jfac005. PMID: 35348720.
Trofa D, Gácser A, Nosanchuk JD. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev. 2008 Oct; 21(4):606-25. Doi: 10.1128/CMR.00013-08. PMID: 18854483; PMCID: PMC2570155.
Vásquez-Zamora, Keila Guillermina, Villalobos-Barboza, Karina, Vergara Espinoza, Martha Arminda, Ventura-Flores, Roberto, & Silva-Díaz, Heber. (2020). Frecuencia y susceptibilidad antifúngica de Candida SPP (no C. albicans) aislada de pacientes de unidades de cuidados críticos de un hospital de tercer nivel del norte del Perú. Horizonte Médico (Lima), 20(4), e1230. https://dx.doi.org/10.24265/horizmed.2020.v20n4.06
Villalobos, Juan M, Castro, José A, Avilés, Alvaro, Peláez, M. Claudia, Somogyi, Teresita, & Sandoval, Lilliana. (2016). Candida parapsilosis: principal causa de candidemia en un hospital de referencia para adultos de Costa Rica. Revista chilena de infectología, 33(2), 159-165. https://dx.doi.org/10.4067/S0716-10182016000200005.
Yamin DH, Husin A, Harun A. Risk Factors of Candida parapsilosis Catheter-Related Bloodstream Infection. Front Public Health. 2021 Aug 12; 9:631865. doi: 10.3389/fpubh.2021.631865. PMID: 34458217; PMCID: PMC8387826.
Zurita Macarlupu, Susana. (2018). Situación de la resistencia antifúngica de especies del género Candida en Perú. Revista Peruana de Medicina Experimental y Salud Publica, 35(1), 126-131. https://dx.doi.org/10.17843/rpmesp.2018.351.3563
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Delia Jessica Astete Medrano, Arturo Alexander Rivas Cárdenas, Juana Amparo Garay Bambarén